This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Apr 11:344:e2591.

doi: 10.1136/bmj.e2591.

Antibiotic drug research and development

Jean-Pierre Paccaud

PMID: 22496301
DOI: 10.1136/bmj.e2591

Editorial

Antibiotic drug research and development

Jean-Pierre Paccaud. BMJ. 2012.

. 2012 Apr 11:344:e2591.

doi: 10.1136/bmj.e2591.

Author

Jean-Pierre Paccaud

PMID: 22496301
DOI: 10.1136/bmj.e2591

No abstract available

PubMed Disclaimer

Comment in

Existing classes of antibiotics are probably the best we will ever have.
Cormican M, Vellinga A. Cormican M, et al. BMJ. 2012 May 15;344:e3369. doi: 10.1136/bmj.e3369. BMJ. 2012. PMID: 22589509 No abstract available.

Comment on

Challenges of drug resistance in the developing world.
Laxminarayan R, Heymann DL. Laxminarayan R, et al. BMJ. 2012 Apr 3;344:e1567. doi: 10.1136/bmj.e1567. BMJ. 2012. PMID: 22491075 No abstract available.
3Rs for innovating novel antibiotics: sharing resources, risks, and rewards.
So AD, Ruiz-Esparza Q, Gupta N, Cars O. So AD, et al. BMJ. 2012 Apr 3;344:e1782. doi: 10.1136/bmj.e1782. BMJ. 2012. PMID: 22491076 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information